Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): A phase I/II study from the hoosier oncology group

Shadia Jalal, David Waterhouse, Martin J. Edelman, Sreenivasa Nattam, Rafat Ansari, Karuna Koneru, Romnee Clark, Arthur Richards, Jingwei Wu, Menggang Yu, Brian Bottema, Angela White, Nasser Hanna

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Purpose: Pemetrexed is a standard treatment against recurrent non-small cell lung cancer (NSCLC), and cetuximab has single-agent activity against NSCLC. This study evaluates the safety and efficacy of the combination of these agents in patients with advanced NSCLC. Patients and Methods: Patients with recurrent NSCLC and an Eastern Cooperative Oncology Group performance status of 0 to 1 were entered. Patients on the phase I portion of the study received cetuximab 400 mg/m2 intravenously (IV) on day -7 followed by weekly doses of cetuximab at 250 mg/m2 IV with escalating doses of pemetrexed every 3 weeks (dose levels: 500, 600, 750, 900 mg/m2) in a standard 3 + 3 design. Once the maximum tolerated dose (MTD) of the combination was determined, patients were enrolled on the phase II portion. The primary end point was to determine the median time to disease progression (TTP) (null hypothesis 12 weeks, alternative hypothesis 24 weeks). Results: Thirty-six patients were enrolled (phase I: n = 13, phase II: n = 23). Patient characteristics included 60.6% men, median age 64 years (range, 37-80 years), 57.6% had performance status 0 and 54.6% had adenocarcinoma histology. The median number of previous regimens was 2 (range, 1-6). The maximum tolerated dose of pemetrexed in combination with cetuximab was determined to be 750 mg/m2. The median TTP was 14.6 weeks. The median survival time was 42 weeks and 1-year survival was 38.5%. Conclusion: The combination of pemetrexed at 750 mg/m2 every 21 days with weekly cetuximab at 250 mg/m2 was feasible; however, in this unselected patient population, the combination regimen does not seem to improve TTP compared with historical controls of either single agent.

Original languageEnglish (US)
Pages (from-to)1420-1424
Number of pages5
JournalJournal of Thoracic Oncology
Issue number11
StatePublished - Nov 2009


  • Cetuximab
  • Pemetrexed
  • Recurrent non-small cell

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): A phase I/II study from the hoosier oncology group'. Together they form a unique fingerprint.

Cite this